GERN

Geron Corp.

Healthcare


Presented:10/13/2022
Price:$2.34
Cap:$0.88B
Current Price:$4.19
Cap:$2.53B

Presented

Date10/13/2022
Price$2.34
Market Cap$0.88B
Ent Value$0.46B
P/E RatioN/A
Book Value$0.38
Div Yield0%
Shares O/S377.82M
Ave Daily Vol3,807,577
Short Int3.58%

Current

Price$4.19
Market Cap$2.53B
Geron Corp. operates as a biotechnology company. It develops a telomerase inhibitor, Imetelstat, in hematologic myeloid malignancies. The firm develops therapeutic products for oncology. The company was founded by Michael D. West on November 28, 1990 and is headquartered in Foster City, CA.

Publicly traded companies mentioned herein: Geron Corp (GERN)

Highlights

The presenter is long shares of Geron Corp (GERN), a biotechnology company specializing in the development of therapeutic cancer products. Investors are excited about an upcoming trial reading in January 2023 that could serve as a significant growth catalyst. Barring any unforeseen issues with the data, the drug should be approved next year and is well-positioned to dominate share in addressable markets. At $2 per share, the stock is positioned for significant gains in the event of approval which should provide an asymmetric risk/reward setup on a binary trial outcome.

  • Signing up and creating account with us unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

  • Signing up and creating account with us unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

Request access to DeMatteo Research for full access

Request Access

Already have an account?

Idea Discussion

Commentor 1 - 2 weeks ago

Signing up and creating account with us, unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

Commentor 1 - 2 weeks ago

Signing up and creating account with us, unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

Idea Discussions display submitted commentary from our investor community.

To read and participate in the discussion with the presenter and investor base, request access to DeMatteo

Request Access

Already have an account?

An error occurred loading this content. Try again later or contact us.